Positron emission tomography (PET) guided therapy of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with or without high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT)
- Conditions
- Diffuse large B-cell lymphoma
- Registration Number
- JPRN-UMIN000004420
- Lead Sponsor
- Japan Study Group for Cell Therapy and Transplantation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 68
Not provided
1.Patients with a history of prior or concurrent malignancies. 2.Patients who are on any medication for diabetes. 3.Patients who have severe complications such as active systematic infection, heart failure, respiratory failure, pulmonary disease, hepatic failure, liver cirrhosis, acute or chronic hepatitis, renal failure, active tuberculosis. 4.Patients with a history of angina or cardiac infarction. Patients with cardiomyopathy. Patients taking anti-arrhythmic drugs. 5.Patients with a history of drug anaphylaxis. 6.Patients with severe mental illness. 7.Patients with a history of lymphoma, leukemia, or MDS. 8.Patients with a history of chemotherapy, cytokine therapy, or antibody therapy for present DLBCL. 9.Patients with primary central nervous system lymphoma or with central nervous system involvement of DLBCL 10.Pregnancy or lactation. 11.Known hepatitis B or C virus infection 12.Known HIV or HTLV-1 infection 13.Patients with any medical condition that in the opinion of the investigator would compromise treatment delivery.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival at 2 years of patients with a persistently positive PET scan after 2 cycles of R-CHOP
- Secondary Outcome Measures
Name Time Method